You are here

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Comparative analysis of synovial inflammation after SARS-CoV-2 infection’ by Alivernini et al
  1. María-del-Carmen López-González1,
  2. Vega Jovani1,
  3. Esperanza Merino2,
  4. Paloma Vela1,3,
  5. Mariano Andrés1,3
  1. 1 Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain
  2. 2 Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, Spain
  3. 3 Departamento de Medicina Clínica, Universidad Miguel Hernandez de Elche, Elche, Spain
  1. Correspondence to Dr Mariano Andrés, Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante 03010, Spain; drmarianoandres{at}gmail.com

https://doi.org/10.1136/annrheumdis-2020-218368

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Few studies have described so far the occurrence of arthritis in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 For this reason, we read with great interest the report by Alivernini et al 2 where they present two cases of polyarthritis in the context of a SARS-CoV-2 infection, with an exhaustive study of synovial tissue. In the immunohistochemical study of both biopsies, they observed inflammatory infiltrates mostly composed of CD3+, CD138+ and CD68+ cells. Furthermore, in the patient with rheumatoid arthritis, case 2, they also detected CD20+ cells. The study of synovial tissue in the context of SARS-CoV-2 arthritis is …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All the authors contributed to the concept and writing of this letter.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests MA declares speaking fees and research grants from Grunenthal, Menarini and Horizon.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles